Genprex Provides Clinical and Corporate Update for Second Quarter 2018
Clinical Development Highlights (
Accentureto provide clinical data management services to help accelerate the clinical development of Genprex’s lead drug candidate, Oncoprex™.
Entered an agreement to use
WIRB-Copernicus Group(WCG) to provide site selection and feasibility services, including Institutional Review Board(IRB) and Institutional Biosafety Committee (IBC) oversight for new clinical trial sites that Genprexanticipates adding to participate in its Phase I/II clinical trial evaluating the combination of OncoprexTM and erlotinib (Tarceva®) in NSCLC.
- Selected 4Clinics as a CRO to provide clinical and regulatory support for the clinical development program in the form of biostatistics, statistical programming and analysis, as well as medical and scientific writing for the Phase I/II clinical trial.
Entered an agreement with
The University of Texas MD Anderson Centerunder which Genprexis sponsoring a pre-clinical study intended to develop a novel therapeutic approach for the treatment of cancer using a combination of the multifactorial tumor suppressor gene TUSC2 and immunotherapy, including the immune checkpoint inhibitors anti-PD1 and/or anti CTLA-4. This study will include the identification of biomarkers to predict the response to TUSC2-immunotherapy combinations.
Amended its agreement with
The University of Texas MD Anderson Cancer Centerto resume patient enrollment in its Phase I/II trial evaluating the combination of Oncoprex™ and erlotinib (Tarceva®) for the treatment of Stage IV non-small cell lung cancer (NSCLC).
Entered an agreement with the
University of Texas at AustinDell Medical School to establish executive offices at the school’s Health Discovery Building, joining the WorkSpaces @ Texas Health CoLab. WorkSpaces @ Texas Health CoLab is designed to identify and support people and companies that share Dell Medical School’s commitment to improving health outcomes to patients and reducing healthcare costs.
Established offices in
Cambridge, MA, where Dr. Julien Pham, President and COO will oversee the clinical development of Genprex’s lead drug candidate, Oncoprex™.
$10 millionprivate placement.
Forward Looking Statements
Statements contained in this press release that are not statements of
historical facts are "forward-looking statements" within the meaning of
the Private Securities Litigation Reform Act of 1995. Because these
statements are subject to risks and uncertainties, the actual results
may differ materially from those expressed or implied by such
forward-looking statements. Such statements include, but are not limited
to, statements about Genprex’s business plans, statements about the
timing and success of the Company’s existing and planned clinical
trials, statements about the development of the Company’s current and
potential future product candidates, statements about the Company’s
plans to seek regulatory approval of its product candidates, and
statements about the services the Company expects to receive from its
development partners and the effect of those services on the development
of Oncoprex. Risks that contribute to the uncertain nature of the
forward-looking statements include: the success, cost and timing of the
Company’s product candidate development activities and current and
planned clinical trials; the Company’s ability to execute on its
strategy; regulatory developments in